Resistance of Bacterial Isolates from Neonates with Suspected Sepsis to Recommended First-Line Antibiotics in Fiji

The changing epidemiology of antimicrobial resistance in Fiji: a descriptive analysis of antimicrobial susceptibility and trends of endemic and emerging pathogens, 2019-2022

Background

There is a paucity of data on antimicrobial resistance in Fiji. The aim of this study was to determine the antimicrobial susceptibility profile of bacterial isolates from clinical samples at Colonial War Memorial Hospital in Fiji.

Methods

This retrospective study reviewed four-year of data from January 1, 2019, through December 31, 2022. Laboratory testing was carried out using locally approved protocols. Selective antimicrobial susceptibility testing was performed whereby only isolates resistant to first line antimicrobials were tested against second line antimicrobials. Only the first isolate of a given species per patient in a single year were included in the analysis. WHONET software and Microsoft Excel were used for analysis.

Findings

A total of 29,222 bacterial isolates were included, 62% (n = 18,084) were Gram-negative bacteria. K. pneumoniae was the most common (n = 5363), followed by E. coli (n = 4321). Extended spectrum beta lactamase (ESBL) production increased from 30% in 2019 to 43% in 2022 amongst K. pneumoniae, and 10%-23% in E coli. There were 733 carbapenem-resistant isolates identified from clinical samples, 61% (n = 445) were A. baumannii, 15% (n = 110) E. coli and 14% (n = 101) P. aeruginosa. Amongst the E. coli isolates tested, susceptibility to meropenem declined from 99% (272/274) in 2019 to 79% (255/325) in 2022. The rate of methicillin resistance amongst Staphylococcus aureus was steady, remaining between 11% and 13%.

Interpretation

This study demonstrated a high rate of MDR amongst Gram-negative bacteria, especially ESBL producing K. pneumoniae and E. coli and carbapenem-resistant A. baumannii. The emergence and rapid spread of carbapenemase producing E. coli in Fiji's largest hospital is of particular concern. There is an urgent need to allocate resources to improve existing capacity and to develop effective multimodal strategies to detect, manage and control the spread of MDR organisms.

Funding

This study was supported by the Medical Research Future Fund through the Australian government (grant number APP 1200970).

Quantification of antimicrobial use in Fijian livestock farms

Antimicrobial resistance (AMR) is a major threat to humans and animals globally. Antimicrobial stewardship has been acknowledged as a primary strategy to tackle AMR. An important first step for antimicrobial stewardship is to quantify antimicrobial use (AMU). In Fiji, there are currently no data on AMU in livestock farms. This study aimed to quantify AMU in different livestock enterprises (beef, dairy, broiler, and layer) and farming systems (backyard, semi-commercial and commercial) in Central and Western divisions of Viti Levu, Fiji. A survey with 210 livestock farmers and 26 managers representing 276 enterprises was conducted between May and September 2019. The difference in AMU between different livestock enterprises and farming systems was investigated using ANOVA. In Fiji, the estimated annual antibiotic use in livestock was lower than the global average (44 compared with 118 mg/PCU). However, this use was concentrated in 56% of participant farms (the remaining 44% did not use antimicrobials). Total estimated quarterly anthelmintic use (20,797 mg) was not affected by farming systems but was highest (P < 0.001) in dairy enterprises (24,120 mg) and lowest in broiler enterprises (4 mg). Quarterly antibiotic use was different between the enterprises regardless of the metrics used to quantify the use (P < 0.05). Total estimated quarterly mg/PCU of antibiotic use was highest (P < 0.001) in broiler enterprises (12.4 mg/PCU) and lowest in beef enterprises (0.2 mg/PCU). For all other ESVAC metrics, total estimated antibiotic use was higher in poultry and lower in cattle enterprises. Backyard systems used less antibiotics (total mg) than commercial systems, but for other metrics, the trend was reversed. The use of both antibiotics and anthelmintics (rather than antibiotics or anthelmintics alone, or no AMU) was associated with dairy enterprises (Χ² = 123, P < 0.001). Further studies should be conducted to quantify and evaluate the drivers of AMU in Fijian livestock farms. In addition, differences in AMU between different enterprises and farming systems suggest that strategies to reduce AMU should be tailored to specific settings.

Antibiotic Resistance in Pacific Island Countries and Territories: A Systematic Scoping Review

Several studies have investigated antimicrobial resistance in low- and middle-income countries, but to date little attention has been paid to the Pacific Islands Countries and Territories (PICTs). This study aims to review the literature on antibiotic resistance (ABR) in healthcare settings in PICTs to inform further research and future policy development for the region. Following the PRISMA-ScR checklist health databases and grey literature sources were searched. Three reviewers independently screened the literature for inclusion, data was extracted using a charting tool and the results were described and synthesised. Sixty-five studies about ABR in PICTs were identified and these are primarily about New Caledonia, Fiji and Papua New Guinea. Ten PICTs contributed the remaining 21 studies and nine PICTs were not represented. The predominant gram-positive pathogen reported was community-acquired methicillin resistant S. aureus and the rates of resistance ranged widely (>50% to <20%). Resistance reported in gram-negative pathogens was mainly associated with healthcare-associated infections (HCAIs). Extended spectrum beta-lactamase (ESBL) producing K. pneumoniae isolates were reported in New Caledonia (3.4%) and Fiji (22%) and carbapenem resistant A. baumannii (CR-ab) isolates in the French Territories (24.8%). ABR is a problem in the PICTs, but the epidemiology requires further characterisation. Action on strengthening surveillance in PICTs needs to be prioritised so strategies to contain ABR can be fully realised.

Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment

PURPOSE OF REVIEW

This review summarizes the main challenges of antimicrobial resistance (AMR) in the neonatal population with a special focus on multidrug-resistant (MDR) Gram-negative pathogens.

RECENT FINDINGS

MDR-Gram-negative bacteria are a great concern in the neonatal population, with a worldwide rise in the reported incidence and with very limited therapeutic options. Extended-spectrum β-lactamase and carbapenem-resistant Enterobacteriaceae (CRE) have been reported as responsible for neonatal ICU outbreaks. Hospital data from low/middle-income countries show high proportions of isolates from neonates resistant to the WHO first-line and second-line recommended treatments. The spread of CRE has resulted in old antibiotics, such as colistin and fosfomycin, to be considered as alternative treatment options, despite the paucity of available data on safety and appropriate dosage.

SUMMARY

Improved global neonatal AMR surveillance programmes including both epidemiology and clinical outcomes are critical for defining the burden and designing interventions. The optimal empiric treatment for neonatal sepsis in settings of high rates of AMR is currently unknown. Both strategic trials of older antibiotics and regulatory trials of new antibiotics are required to improve clinical outcomes in MDR-Gram-negative neonatal sepsis.